METASTATIC PROSTATE CANCER

This phase 3 trial tests whether giving denosumab every 12 weeks is as effective as the standard every 4 weeks at preventing bone complications (like fractures or need for radiation) in people with metastatic breast or prostate cancer that has spread to the bone. About 1380 parti…

This study tests a new drug (AZD5305) combined with standard hormone therapies in people with metastatic prostate cancer that has spread. The goal is to check safety, how the drug moves through the body, and early signs of effectiveness. About 174 adults whose cancer has spread a…

This early-stage study tests two oral drugs, darolutamide and abemaciclib, plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combo can shrink tumors before surgery. …

This study tests whether a combination of two drugs (cabozantinib and atezolizumab) works better than standard hormone therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. About 575 men who have already tried one hormone therapy will be …

This early-stage study tests a new drug called ARX517, alone or with other prostate cancer treatments, in 183 men with metastatic prostate cancer that has spread. The main goal is to check the drug's safety and find the best dose. Participants must have prostate cancer that hasn'…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy can better control metastatic prostate cancer that hasn't been treated yet. About 28 men with newly diagnosed, hormone-sensitive prostate cancer that has …

This study tests whether adding a high-dose, precise type of radiation called SBRT to standard treatments (like hormone therapy or chemotherapy) can delay cancer progression in people with solid tumors that have spread to 1 to 5 spots in the bones. It includes adults up to age 75…

This early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants must have meta…

This study tests whether adding a chemotherapy drug called carboplatin to a targeted radiation treatment (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that no longer responds to hormone therapy. About 37 participants will receive the combination to …

This study tests a mix of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer. The goal is to see if the combination can stop the cancer from growing for at least 6 months. Participants receive up to 10 cycles of…

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better find prostate cancer that has spread or come back after treatment. About 360 men with high-risk or recurrent prostate cancer will get a PET/CT scan using this tracer. The goal is to improve how doctor…

This study tests whether a new radioactive tracer called 18F-DCFPyL can better detect where prostate cancer has spread in the body compared to a standard tracer. About 96 adults with metastatic prostate cancer will receive both types of scans and be followed for one year. The goa…

This study tracks how well treatment is working in men with metastatic hormone-sensitive prostate cancer using special PET scans (PSMA-PET). Twenty participants will get a scan before starting standard therapy and another after 6 months. The goal is to see if these scans can help…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…

This study looks at whether analyzing DNA from cancer cells in the blood can help doctors choose the best treatment for men with metastatic prostate cancer. About 192 men will give extra blood samples during their standard care. The goal is to improve future treatment decisions, …

This study tests whether a special type of PET scan, called PSMA PET, can track prostate cancer more accurately than usual scans like CT or bone scans. About 58 men with progressive or newly diagnosed prostate cancer will get PSMA PET scans over time. The goal is to see if change…

This observational study aims to understand why some advanced prostate cancers become resistant to hormone therapy. Researchers will collect tumor samples from 30 patients before and during treatment to look for changes in immune cells and cancer markers. The goal is to find earl…